STOCK TITAN

REGENERATIVE MEDICAL TECH (RMTG) Net Income by Year

RMTG

REGENERATIVE MEDICAL TECH reported a net loss of $7.8M in fiscal year 2025. This represents a decrease of 40.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $9.4M net loss. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters REGENERATIVE MEDICAL TECH has filed alongside them.

FY2025 annual
Net Income -$7.8M
YoY -40.4%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RMTG Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-K
Net Income-$9.4M-$7.8M-40.4%-$5.6M+43.3%-$9.8M-78.2%-$5.5M+57.3%-$12.9MN/AN/AN/AN/A

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

RMTG Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$2.9M-101.3%-$876K-15.3%-$1.3M-96.7%-$4.4M-390.8%-$1.4M+30.5%-$760K+61.2%-$638K-149.3%-$887K+84.9%-$2.1M-2.3%-$2.0M-17.4%-$256K+74.2%-$5.9M-335.7%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More REGENERATIVE MEDICAL TECH financials

Frequently Asked Questions

What was REGENERATIVE MEDICAL TECH's net income in fiscal year 2025?

REGENERATIVE MEDICAL TECH reported a net loss of $7.8M in fiscal year 2025.

How fast is REGENERATIVE MEDICAL TECH's net income growing?

REGENERATIVE MEDICAL TECH (RMTG) net income fell by 40.4% year over year, from -$5.6M to -$7.8M in fiscal year 2025.

What is REGENERATIVE MEDICAL TECH's net income over the last twelve months?

REGENERATIVE MEDICAL TECH (RMTG) reported a $9.4M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

REGENERATIVE MEDICAL TECH (RMTG) reported -$2.9M in net income in Q2 2026. This represents a decrease of 101.3% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what REGENERATIVE MEDICAL TECH (RMTG) reported on that line in every period on record.